

PARTICULARS TO APPEAR ON THE OUTER PACKAGE {CARDBOARD BOX}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Vomend 5 mg/ml solution for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:

Active substance:

Metoclopramide (as hydrochloride monohydrate)	4.457 mg
Equivalent to metoclopramide hydrochloride	5 mg

3. PACKAGE SIZE

5 ml, 10 ml, 20 ml, 25 ml, 30 ml and 50 ml

4. TARGET SPECIES

Dogs, cats



5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Intramuscular or subcutaneous use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Shelf life after first opening the immediate packaging: 28 days.

Once opened, use by: ___/___/___

9. SPECIAL STORAGE PRECAUTIONS

Store in the original package.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Eurovet Animal Health B.V.

14. MARKETING AUTHORISATION NUMBERS

UK(GB) Vm 16849/5013

UK(NI) Vm 16849/3013

15. BATCH NUMBER

Lot {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE {GLASS
VIAL/20/25/30/50 ml}**

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Vomend 5 mg/ml solution for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:

Active substance:

Metoclopramide (as hydrochloride monohydrate)	4.457 mg
Equivalent to metoclopramide hydrochloride	5 mg

3. TARGET SPECIES

Dogs, cats



4. ROUTES OF ADMINISTRATION

Read the package leaflet before use.

5. WITHDRAWAL PERIODS

6. EXPIRY DATE

Exp. {mm/yyyy}

Shelf life after first opening the immediate packaging: 28 days.

Once opened, use by: ___/___/___

7. SPECIAL STORAGE PRECAUTIONS

Store in the original package.

8. NAME OF THE MARKETING AUTHORISATION HOLDER

Eurovet Animal Health B.V.

9. BATCH NUMBER

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS {GLASS VIAL/5/10 ml}**

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Vomend



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

5 mg metoclopramide hydrochloride per ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Vomend 5 mg/ml solution for injection for dogs and cats

2. Composition

Each ml contains:

Active substance:

Metoclopramide (as hydrochloride monohydrate)	4.457 mg
equivalent to metoclopramide hydrochloride	5 mg

Excipients:

Benzyl alcohol (E1519)	18 mg
------------------------	-------

Clear, colourless, aqueous solution.

3. Target species

Dogs, cats

4. Indications for use

Symptomatic treatment of vomiting and reduced gastrointestinal motility associated with gastritis, pyloric spasm, chronic nephritis and digestive intolerance to some drugs.

5. Contraindications

Do not use in cases of gastrointestinal perforation or obstruction.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. Special warnings

Special precautions for safe use in the target species:

The dosage must be adapted in animals with renal or hepatic insufficiency (due to an increase in the risk of side effects). Avoid administration to animals with epilepsy. The dosage should be carefully observed, especially in cats and small breed dogs. Following prolonged vomiting, consideration should be given to fluid and electrolyte replacement therapy.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after administration to the animal.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

In case of accidental exposure by spillage onto the skin or eyes, wash immediately with abundant water. If an adverse effect occurs, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

Laboratory studies in laboratory animals have not produced any evidence of teratogenic or foetotoxic effects. However, studies in laboratory animals are limited and the safety of the active substance has not been evaluated in the target species. Use only according to the benefit-risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

In cases of gastritis, avoid the co-administration of anticholinergic drugs (atropine) as they may counteract the effects of metoclopramide on gastrointestinal motility.

In cases of simultaneous diarrhoea, there is no contraindication to the use of anticholinergic drugs.

Concurrent use of metoclopramide with neuroleptics derived from phenothiazine (acepromazine) and butyrophenones increases the risk of extrapyramidal effects (see section "Adverse events").

Metoclopramide can potentiate the action of central nervous system depressants. If used concurrently, it is advised to use the lowest dosage of metoclopramide to avoid excessive sedation.

Overdose:

Most of the clinical signs reported after an overdose are well known extrapyramidal side effects (see section "Adverse events").

In the absence of a specific antidote, it is recommended to offer a calm environment to the animal until the extrapyramidal side effects disappear.

Metoclopramide being rapidly metabolised and eliminated, side effects generally disappear quickly.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

7. Adverse events

Dogs, cats:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Extrapyramidal effects ^a (agitation, ataxia, abnormal positions and/or movements, prostration, tremors, aggression, vocalisation) Allergic reaction
---	--

^a The observed effects are transient and disappear when treatment is stopped.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Intramuscular or subcutaneous use.

0.5 mg metoclopramide hydrochloride per kg body weight, if necessary repeated every 6-8 hours.

9. Advice on correct administration

5 mg/10 kg (equivalent to 1 ml/10 kg)

Injections can be repeated every 6-8 hours.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Store in the original package.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: 28 days

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

MA number: UK(GB) Vm 16849/5013

UK(NI) Vm 16849/3013

Glass vial with a rubber stopper and cap.

Pack sizes:

Cardboard box containing 1 vial of 5 ml, 10 ml, 20 ml, 25 ml, 30 ml and 50 ml.

Not all pack sizes may be marketed.

15. PID link (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release:

Eurovet Animal Health B.V.
Handelsweg 25
5531 AE Bladel
The Netherlands

Local representatives and contact details to report suspected adverse reactions:

Dechra Veterinary Products Limited
Sansaw Business Park
Hadnall
Shrewsbury
Shropshire
SY4 4AS
Tel: +44 (0) 1939 211200

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

POM-V

Gavin Hall

Approved: 24 July 2025